Effective treatment with programmed cell death protein‐1 antibody, chidamide and conventional chemotherapy for hepatosplenic γδ T‐cell lymphoma: A case report and literature review.

Hepatosplenic T cell lymphoma (HS TCL), first reported in 1990,4 is derived mostly from a subset of T-cell lymphocytes.5 It is characterized by hepatomegaly, splenomegaly and pancytopenia, and more rarely lymphadenopathy. T cells are divided into T cells and T cells according to their receptor types.3 TCR of T cells, representing 1%-5% of all peripheral blood lymphocytes, are composed of and polypeptide chains with variable and constant regions. G, A flow cytometry analysis of the bone marrow aspirates identified an increased level of T-cells, confirming bone marrow involvement of the hepatosplenic T-cell lymphoma gl T-cell antigen receptor is a heterodimer molecule composed of either or chains. Hepatosplenic T-cell lymphoma (HSTCL), a rare subtype of peripheral T-cell lymphoma (PTCL), accounts for 3.0% of all T-cell lymphomas in the North America but only 0.2% in Asia.1 It is characterized by an aggressive behavior and a poor patient prognosis. [Extracted from the article]